Ueoka H, Ohnoshi T, Numata T, Kawahara S, Nishii K, Yonei T, Yamashita H, Moritaka T, Kiura K, Uji H
Department of Medicine, Okayama University Medical School.
Nihon Kyobu Shikkan Gakkai Zasshi. 1990 Dec;28(12):1581-7.
The pattern of relapse was analyzed in patients with small cell lung cancer (SCLC). Of 180 patients treated with intensive combination chemotherapy between 1976 and 1987, 75 achieved complete response (CR). Of 47 patients with limited disease (LD), 20 (43%) initially relapsed in the chest and 7 (15%) in the brain. Among 27 patients with extensive disease (ED), the chest was also the most frequent site of relapse (44%) followed by the brain (19%). In LD patients who had received chemotherapy plus chest irradiation, the initial relapse rate and the cumulative relapse rate in the chest at 2 years were only 29% and 35.4%, respectively. These rates were significantly lower compared with the rates of 69% and 76.5% for patients who had received chemotherapy alone (p less than 0.05). Survival was improved to some extent by the addition of chest irradiation, but not significantly, however, the long-term survival rate favored those receiving chest irradiation. Prophylactic cranial irradiation (PCI) reduced the frequency of brain relapse and significantly improved the survival of SCLC patients achieving CR. The median survival time and 5-year survival rate of patients who received PCI were 23.1 months and 26.7%, which these figures were only 14.0 months and 8.3% for those who had not respectively. Analysis using Cox's proportional hazard model showed that PCI was the greatest prognostic factor favoring the SCLC patients achieving CR. These results indicate that chest irradiation and PCI in conjunction with intensive combination chemotherapy are effective for cases of SCLC with CR.
对小细胞肺癌(SCLC)患者的复发模式进行了分析。在1976年至1987年间接受强化联合化疗的180例患者中,75例获得完全缓解(CR)。在47例局限性疾病(LD)患者中,20例(43%)最初在胸部复发,7例(15%)在脑部复发。在27例广泛性疾病(ED)患者中,胸部也是最常见的复发部位(44%),其次是脑部(19%)。在接受化疗加胸部放疗的LD患者中,2年时的初始复发率和胸部累积复发率分别仅为29%和35.4%。与仅接受化疗的患者的69%和76.5%相比,这些比率显著更低(p<0.05)。胸部放疗在一定程度上改善了生存率,但不显著,然而,长期生存率有利于接受胸部放疗的患者。预防性颅脑照射(PCI)降低了脑部复发的频率,并显著改善了达到CR的SCLC患者的生存率。接受PCI的患者的中位生存时间和5年生存率分别为23.1个月和26.7%,而未接受PCI的患者分别仅为14.0个月和8.3%。使用Cox比例风险模型进行的分析表明,PCI是有利于达到CR的SCLC患者的最大预后因素。这些结果表明,胸部放疗和PCI联合强化联合化疗对达到CR的SCLC病例有效。